清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy

医学 瑞戈非尼 无容量 内科学 易普利姆玛 结直肠癌 肿瘤科 癌症 队列 临床终点 进行性疾病 实体瘤疗效评价标准 化疗 临床试验 免疫疗法
作者
Marwan Fakih,Jaideep Singh Sandhu,Dean W. Lim,Xiaochen Li,Sierra Li,Chongkai Wang
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (5): 627-627 被引量:114
标识
DOI:10.1001/jamaoncol.2022.7845
摘要

Importance: Immunotherapy combinations with activity in patients with microsatellite stable (MSS) metastatic colorectal cancer need to be identified. Objective: To determine the recommended phase 2 dose (RP2D) of regorafenib, ipilimumab, and nivolumab (RIN) and evaluate its activity in an expansion cohort of patients with MSS metastatic colorectal cancer. Design, Setting, and Participants: This nonrandomized clinical trial was a single-center 3 + 3 dose de-escalation study with an effectiveness expansion cohort at the RP2D. After the identification of the RP2D, a study amendment was executed to explore a regorafenib dose optimization strategy to mitigate skin-related toxic effects. Study enrollment occurred between May 12, 2020, and January 21, 2022. The trial was conducted at a single academic center. A total of 39 patients with MSS metastatic colorectal cancer whose disease progressed after standard chemotherapy and who had not received prior regorafenib or anti-programmed cell death protein 1 therapy were included. Interventions: Patients received regorafenib daily for 21 days every 4 weeks; fixed-dose ipilimumab, 1 mg/kg, intravenously every 6 weeks; and fixed-dose nivolumab, 240 mg intravenously every 2 weeks. Patients were treated until progression, unacceptable toxic effects, or completion of 2 years of therapy. Main Outcomes and Measures: The primary end point was RP2D selection. Secondary end points were safety and overall response rate (ORR) according to the Response Evaluation Criteria in Solid Tumours at the RP2D level. Results: A total of 39 patients were enrolled, 23 (59.0%) were female, median age was 54 years (range, 25-75 years), 3 were Black (7.7%), and 26 were White (66.7%). No dose-limiting toxic effects were noted in the first 9 patients at the starting dose of RIN, with regorafenib dosed at 80 mg daily. No dose de-escalation was needed. This dose was declared the RP2D. Twenty more patients were enrolled at this level. The ORR, median progression-free survival (PFS), and overall survival (OS) in the RP2D cohort were 27.6%, 4 months (IQR, 2-9 months), and 20 months (IQR, 7 months to not estimable), respectively. For the 22 patients without liver metastases, the ORR, PFS, and OS were 36.4%, 5 months (IQR, 2-11), and greater than 22 months, respectively. A dose optimization cohort with regorafenib at 40 mg/d on cycle 1 and 80 mg/d on cycle 2 and beyond was associated with lower skin and immune toxic effects but had limited activity with stable disease for 5 of 10 patients as the best response. Conclusions and Relevance: Results of this nonrandomized clinical trial suggest that RIN at the RP2D demonstrated interesting clinical activity in patients with advanced MSS colorectal cancer without liver metastases. These findings should be confirmed in randomized clinical trials. Trial Registration: ClinicalTrials.gov Identifier: NCT04362839.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NN完成签到,获得积分10
4秒前
等待戈多发布了新的文献求助10
12秒前
笑点低的如萱完成签到,获得积分10
14秒前
TingtingGZ发布了新的文献求助10
14秒前
chenchen完成签到,获得积分10
20秒前
Wang发布了新的文献求助10
21秒前
21秒前
心灵美懿轩完成签到,获得积分10
26秒前
无限鸣凤完成签到,获得积分10
45秒前
linllll完成签到,获得积分10
47秒前
魔幻的凝丝完成签到,获得积分10
48秒前
我是老大的应助被TingtingGZ采纳,获得10
52秒前
drkyy完成签到,获得积分10
56秒前
顺利秋灵完成签到,获得积分10
1分钟前
等待戈多完成签到,获得积分10
1分钟前
漂亮的颤完成签到,获得积分10
1分钟前
1分钟前
TingtingGZ发布了新的文献求助10
1分钟前
科研通AI6.2的应助被TingtingGZ采纳,获得10
1分钟前
metoo完成签到,获得积分10
1分钟前
迷路曼荷完成签到,获得积分10
1分钟前
文艺的纸鹤完成签到,获得积分10
1分钟前
高兴战斗机完成签到,获得积分10
2分钟前
2分钟前
2分钟前
小胖子完成签到 ,获得积分10
2分钟前
ze完成签到 ,获得积分10
2分钟前
迷你的蜜粉完成签到,获得积分10
2分钟前
如意嘉熙完成签到,获得积分10
2分钟前
蜗牛好好飞完成签到,获得积分10
2分钟前
悦耳乘风完成签到,获得积分10
2分钟前
La完成签到,获得积分10
2分钟前
风中睫毛完成签到,获得积分10
3分钟前
冷酷的易文完成签到,获得积分10
3分钟前
molihuakai的应助被科研通管家采纳,获得10
3分钟前
Khan完成签到,获得积分10
3分钟前
天天快乐的应助被Wang采纳,获得10
3分钟前
公子小白完成签到,获得积分10
3分钟前
迷路牛青完成签到,获得积分10
3分钟前
limengyao完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173213
求助须知:如何正确求助?哪些是违规求助? 9565567
关于积分的说明 21780496
捐赠科研通 7767342
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555730
邀请新用户注册赠送积分活动 2476697